Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

The Nifty Pharma index closed on a positive note on Tuesday. Shares of Glenmark Pharmaceuticals Ltd.(up 3.55 per cent), Ipca ...

Gland Pharma Ltd.(down 0.36 per cent) and Natco Pharma Ltd.(down 0.24 per cent) were the top losers on the index. The Nifty ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

Current health highlights include Sanofi, GSK, and CSL expanding bird flu vaccine efforts in the U.S. following a multi-state ...

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and ...

Wyoming Attorney General Bridget Hill on Friday announced that a settlement with a French pharmaceutical company will cap the ...

Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...

The litigation comes as pharmacy benefit managers Express Scripts, CVS Caremark and Optum Rx have faced growing criticism over their role in high drug costs — including a recent lawsuit from the ...

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.